GINGERA MIDLIFE, UNDERSTOOD
← The reading room
Hormones & treatment · 8 MIN READ

Estetrol E4 Reaches FDA Review: What the Hot-Flash Trials Show

Full original restored

Pharmacology, hot-flash trials and long-term safety studies each answer a different question.

Editorial image
In this article
Complete manuscript restored from the archive, with a full English translation. Original medical claims have been preserved for review; medical and regional terminology review remain pending. This is educational reading, not individual medical advice.

Can an estrogen produced by the fetal liver relieve menopausal hot flashes? The answer for estetrol (E4) is moving from the laboratory into regulatory review. On 2026-10-14, Gedeon Richter announced that the US FDA had accepted the new drug application for its oral E4 preparation, FYLREVY, proposed for moderate-to-severe menopause-related vasomotor symptoms (VMS). The company expects review to finish in the third quarter of 2027. Acceptance means the application has entered review; it does not mean the FDA has determined that it is effective or safe, or approved it for sale.[1]

This article first answers three questions: why E4 is being studied, what existing randomized trials have actually demonstrated, and which safety questions remain unanswered. In particular, “smaller changes in coagulation markers” must be distinguished from “fewer clinical blood clots.”

01 What is E4, and why is it called a “selective” estrogen?

During pregnancy, E4 is synthesized mainly by the fetal liver; pharmaceutical E4 is manufactured from plant-derived starting materials through chemical processes. It remains an estrogen, rather than a phytoestrogen, and sharing the structure of an endogenous pregnancy molecule does not automatically make it safer than existing medicines. E4 is already combined with drospirenone in oral contraceptives in some countries, but contraceptive doses, accompanying medicines, and target populations differ. Experience in that indication cannot be treated directly as long-term safety evidence for menopausal hormone therapy (MHT).[1,2]

Pharmacological studies show that E4 interacts with estrogen receptor α somewhat differently from estradiol (E2); animal, cell, and early human studies suggest it may have smaller effects on some liver-derived proteins and coagulation markers. That is a reasonable starting point for research. It does not yet establish that it is “safer for the breast” or “will not cause blood clots,” nor can a single laboratory measure rule out contraindications for a patient.[2,3]

Original article illustration

Skógafoss, Iceland | Photograph by JavierOlivares, CC BY-SA 4.0.

02 Approved in the EU, still under review in the US: clarify regulatory status

The European Commission granted FYLREVY marketing authorization in March 2026. According to the manufacturer's announcement, the 14.2 mg and 18.9 mg strengths can be used for estrogen-deficiency symptoms in postmenopausal women with a uterus at least 12 months after their last period; the 18.9 mg strength is also authorized for those who have had a hysterectomy. The product is already marketed in countries including Hungary, Czechia, Slovakia, Finland, and Sweden. The US application concerns moderate-to-severe VMS. European approval does not automatically confer US approval, and the indications in the two regions are not interchangeable.[1]

Region Status as of 2026-10 Clinical interpretation
EU/European Economic Area Marketing authorization granted in March 2026; indications and strengths follow local labeling Approval does not replace long-term postmarketing safety monitoring
United States FDA has accepted the NDA; the company expects review to finish in the third quarter of 2027 Acceptance is not approval, and the review date may change
China This article did not verify an approved label for this menopause indication Overseas news cannot establish that it may be prescribed domestically; consult drug-regulatory information

Another detail can be obscured by dose figures: research papers use trial doses of 15 mg and 20 mg, whereas the company's announcement lists European marketed strengths of 14.2 mg and 18.9 mg. Read each trial and label using its own stated conventions; similar-looking numbers are not a basis for self-conversion or prescribing.[1,4]

Original article illustration

Senate Square, Helsinki, Finland | Photograph by JIP, CC BY-SA 4.0.

03 Randomized trials can answer “Did hot flashes improve?”

The published E4COMFORT I study is a multicenter, double-blind, placebo-controlled phase III trial. It randomized 640 postmenopausal women aged 40–65 with at least 7 moderate-to-severe hot flashes daily or at least 50 weekly to oral E4 15 mg, 20 mg, or placebo each day, comparing changes in symptom frequency and severity at week 4 and week 12. Its primary outcomes were symptoms, rather than heart attacks, fractures, breast cancer, or venous thrombosis.[4]

Compared with placebo, both doses reduced the weekly number of moderate-to-severe hot flashes at week 4 and week 12. Read the figures as “adjusted between-group differences,” rather than the total reduction from baseline for every participant:[4]

E4 dose Week 4: difference in weekly frequency Week 12: difference in weekly frequency
15 mg 9.63 fewer episodes (P=0.038) 16.41 fewer episodes (P<0.001)
20 mg 14.94 fewer episodes (P<0.001) 22.49 fewer episodes (P<0.001)

At week 12, adjusted differences in symptom severity scores versus placebo were −0.54 and −0.66, respectively. Meanwhile, the study reported drug-related treatment-emergent adverse events in 51.6%, 57.3%, and 20.6% of the 15 mg, 20 mg, and placebo groups, respectively; discontinuation because of treatment-emergent adverse events occurred in 6.6%, 7.5%, and 2.3%, respectively. Effective does not mean free of side effects, and efficacy figures should not be selectively quoted.[4]

Original article illustration

Geirangerfjord, Norway | Photograph by Simo Räsänen, CC BY-SA 3.0.

The company's figure of 2576 participants across E4COMFORT I and II represents the total enrollment in the two studies, including randomized efficacy comparisons and long-term safety cohorts; it must not be described as “all 2576 randomized against placebo.” The peer-reviewed E4COMFORT I paper currently provides directly checkable efficacy figures. The design paper describes both studies and notes that participants with a uterus received progestogen during the safety phase for endometrial evaluation.[1,5]

04 How far are stable coagulation markers from “fewer blood clots”?

A dose-finding study published in Climacteric analyzed thrombin-generation assay data from 168 postmenopausal women, including 31 receiving placebo and 32 receiving oral E4 15 mg; after 12 weeks, mean thrombin-generation curves in all dose groups remained within the study-defined baseline reference range. The authors regarded this as a signal of smaller effects on hemostasis. The sample size and follow-up were insufficient to compare real-world venous thrombosis incidence, much less establish that E4 is safer than transdermal estradiol.[3]

The same standard applies to breast evidence: cell-proliferation markers or short-term breast measures are not breast cancer incidence. For women with a uterus, systemic estrogen also involves endometrial protection; whether to combine it with a progestogen, and the specific regimen and indication, should follow approved local labeling and individual medical history. The US application is still under review, so its final risk label cannot be written in advance.[1,2,5]

Where risk claims should stop: “Different pharmacological mechanisms and short-term surrogate markers warrant further study” is supported by evidence; “no clotting risk,” “no increased breast cancer risk,” or “superior to transdermal regimens” currently lack corresponding clinical outcome evidence.

Original article illustration

Stockholm waterfront, Sweden | Photograph by Holger.Ellgaard, CC BY-SA 3.0.

05 People struggling with hot flashes do not need to wait for the next medicine

Current MHT decisions first consider symptom severity, age and time since menopause, uterine status, and individual risks including thrombosis and breast disease, then discuss administration route and reassessment. The North American Menopause Society's 2022 statement identifies systemic hormone therapy as an effective treatment for VMS; for people under 60 or less than 10 years since menopause, without contraindications and with a treatment indication, the overall benefit–risk ratio is generally more favorable. This finding applies to existing evaluated treatment strategies and cannot directly become an approval conclusion for E4.[6]

People unable or unwilling to use hormones also deserve symptom assessment and discussion of nonhormonal treatments. Abnormal uterine bleeding, persistent palpitations, sleep disorders, and other possible causes require separate clinical attention. The drug pipeline concerns the future; current symptoms should not be set aside because an application remains under review in the US.

Original article illustration

Hallgrímskirkja, Reykjavík, Iceland | Photograph by Andreas Tille, CC BY-SA 4.0.

06 Four things to check when reading this kind of clinical news

Claim encountered Question to return to
“Accepted by the FDA” Submitted, accepted, or formally approved? For which indication?
“2576 participants across two phase III trials” How many were in randomized efficacy cohorts versus long-term safety cohorts?
“More favorable for coagulation and the breast” Were surrogate markers measured, or actual clotting and cancer events over sufficiently long follow-up?
“Already marketed in Europe” What do local labels specify about marketed strengths and uterine status?

E4 deserves attention because it has verifiable randomized-trial evidence of symptom benefit and raises pharmacological questions distinct from traditional estrogens. What can truly change its clinical position next is a clear approved label, more substantial long-term safety data, and direct comparisons with existing treatments. Until then, a medicine under review cannot be presented as having resolved MHT's clotting and breast concerns.

Original article illustration

Winter in Finland's Lake Saimaa region | Photograph by Orrling, CC BY-SA 3.0.

Sources, references, and evidence conventions

① Gedeon Richter. FDA Submission Acceptance of NDA for FYLREVY. 2026-10-14. Regulatory status, approved European strengths, and overall enrollment in the two studies come from a company announcement, rather than an FDA approval announcement.

② Gérard C, Foidart JM. Estetrol: From Preclinical to Clinical Pharmacology and Advances in the Understanding of the Molecular Mechanism of Action. Drugs R D. 2023. DOI: 10.1007/s40268-023-00419-5. A pharmacological review, rather than a long-term outcome trial.

③ Morimont L, et al. Low thrombin generation in postmenopausal women using estetrol. Climacteric. 2024. DOI: 10.1080/13697137.2023.2292066. Short-term coagulation surrogate markers.

④ Simoncini T, et al. Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled study. Maturitas. 2026. DOI: 10.1016/j.maturitas.2026.108965. The efficacy and adverse-event figures in this article come from this randomized trial's abstract.

⑤ Panay N, et al. The design of the E4COMFORT I and II trials. Maturitas. 2026. DOI: 10.1016/j.maturitas.2025.108781. Cohort designs of the two studies.

⑥ The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29:767–794. DOI: 10.1097/GME.0000000000002028. A reference for current clinical MHT decisions.

Photography credits and licenses: all images are from Wikimedia Commons; the cover was cropped and given branded layout, while the other images were resized from the originals.

This article interprets research; it is not a pharmaceutical advertisement or individualized prescribing advice. Approvals and labels may change across regions. Clinical use should follow the relevant local regulator and professional assessment.

SOURCE NOTES

Read the source material

The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.

GINGERA / COMMUNITY

A good question starts a conversation.

Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.

Create a free accountDiscuss hot flashes